Bharat Bio looks for partners to manufacture, distribute iNCOVACC globally

Its local production ramp-up remains unhurried as demand for boosters reduces

Bharat Biotech, Covaxin

Bharat Biotech claimed that iNCOVACC is the world’s first Intranasal vaccine for Covid to receive approval for the primary 2-dose schedule, and heterologous booster dose

Sohini Das Mumbai
After Bharat Biotech International’s Monday announcement of its Covid intranasal vaccine iNCOVACC (BBV154) receiving the Central Drugs Standard Control Organisation approval as heterologous booster dose under restricted use in emergency situation for ages 18 and above in India, the Hyderabad-headquartered biotechnology company is scouting for global partners to manufacture and distribute the world’s first non-invasive needle-free vaccine.

The company has started production of iNCOVACC in India, but is slow to ramp up in the absence of demand.

“There is demand from the private market (for this vaccine) as a booster shot. Production is continuing, but deployed capacity is limited due to lack of demand,” informs a company source.

First Published: Nov 29 2022 | 7:17 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to